Allianz Asset Management GmbH boosted its position in shares of AstraZeneca plc (NYSE:AZN) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 96,395 shares of the company’s stock after acquiring an additional 18,297 shares during the period. Allianz Asset Management GmbH’s holdings in AstraZeneca were worth $3,345,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of AstraZeneca in the 4th quarter valued at approximately $101,000. Valeo Financial Advisors LLC bought a new stake in AstraZeneca during the 3rd quarter worth approximately $133,000. Calton & Associates Inc. bought a new stake in AstraZeneca during the 4th quarter worth approximately $181,000. Wealthcare Advisory Partners LLC bought a new stake in AstraZeneca during the 3rd quarter worth approximately $184,000. Finally, Neumann Capital Management LLC bought a new stake in AstraZeneca during the 4th quarter worth approximately $202,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.
AstraZeneca plc (AZN) opened at $34.57 on Tuesday. AstraZeneca plc has a 1-year low of $28.43 and a 1-year high of $36.70. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $87,612.88, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 2.06 and a beta of 0.71.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 EPS. equities analysts expect that AstraZeneca plc will post 1.69 earnings per share for the current year.
The business also recently declared a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were paid a $0.95 dividend. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend was Thursday, February 15th. AstraZeneca’s dividend payout ratio (DPR) is currently 57.81%.
A number of equities research analysts recently commented on the company. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Monday. Jefferies Group upgraded AstraZeneca from a “hold” rating to a “buy” rating and increased their price target for the stock from $28.43 to $36.70 in a research report on Monday. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Sanford C. Bernstein increased their price target on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Finally, Leerink Swann increased their price target on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average price target of $36.32.
TRADEMARK VIOLATION WARNING: “Allianz Asset Management GmbH Raises Position in AstraZeneca plc (AZN)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/20/allianz-asset-management-gmbh-raises-position-in-astrazeneca-plc-azn.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.